📊 INDV Key Takeaways
Is INDV a Good Investment? Thesis Analysis
Despite strong profitability metrics with 80.2% gross margin and 16.9% net margin, Indivior faces critical financial distress with negative stockholders' equity (-$98M) and deteriorating cash flow generation. The company's negative operating and free cash flow (-$93M), combined with current ratio of 0.71x, indicates severe liquidity constraints that outweigh near-term profitability, posing significant solvency risk.
Why Buy INDV? Key Strengths
- Exceptional gross margin of 80.2% demonstrates strong pricing power and cost structure typical of specialty pharmaceuticals
- Solid operating margin of 21.1% and net margin of 16.9% reflect operational efficiency and profitability at the bottom line
- Robust revenue growth of 4.3% YoY shows steady demand for products despite market competition
INDV Investment Risks to Consider
- Negative stockholders' equity of -$98M indicates the company is technically insolvent on a balance sheet basis with liabilities exceeding assets
- Negative free cash flow of -$93M and negative operating cash flow of -$27M signal the company cannot fund operations and capital needs from internal cash generation
- Severely stressed liquidity with current ratio of 0.55x (quick ratio) and 0.71x (current ratio), well below the 1.0x safety threshold, creating acute refinancing risk
Key Metrics to Watch
- Operating cash flow trend - critical to monitor whether negative OCF can return to positive territory
- Stockholders' equity trajectory - any further deterioration could trigger covenant violations or debt restructuring
- Current ratio and cash balance - must maintain minimum liquidity to service $290M long-term debt and operations
INDV Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
INDV Profitability Ratios
INDV vs Healthcare Sector
How Indivior Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INDV Overvalued or Undervalued?
Based on fundamental analysis, Indivior Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INDV Balance Sheet & Liquidity
INDV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Indivior Pharmaceuticals, Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $-0.92 indicates the company is currently unprofitable.
INDV Growth Metrics (YoY)
INDV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $307.0M | $7.0M | $0.05 |
| Q2 2025 | $299.0M | $7.0M | $0.05 |
| Q1 2025 | $266.0M | $7.0M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INDV Capital Allocation
INDV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Indivior Pharmaceuticals, Inc. (CIK: 0001625297)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INDV
What is the AI rating for INDV?
Indivior Pharmaceuticals, Inc. (INDV) has an AI rating of SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INDV's key strengths?
Claude: Exceptional gross margin of 80.2% demonstrates strong pricing power and cost structure typical of specialty pharmaceuticals. Solid operating margin of 21.1% and net margin of 16.9% reflect operational efficiency and profitability at the bottom line.
What are the risks of investing in INDV?
Claude: Negative stockholders' equity of -$98M indicates the company is technically insolvent on a balance sheet basis with liabilities exceeding assets. Negative free cash flow of -$93M and negative operating cash flow of -$27M signal the company cannot fund operations and capital needs from internal cash generation.
What is INDV's revenue and growth?
Indivior Pharmaceuticals, Inc. reported revenue of $1.2B.
Does INDV pay dividends?
Indivior Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find INDV SEC filings?
Official SEC filings for Indivior Pharmaceuticals, Inc. (CIK: 0001625297) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INDV's EPS?
Indivior Pharmaceuticals, Inc. has a diluted EPS of $1.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INDV a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Indivior Pharmaceuticals, Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INDV stock overvalued or undervalued?
Valuation metrics for INDV: ROE of N/A (sector avg: 15%), net margin of 16.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INDV stock in 2026?
Our dual AI analysis gives Indivior Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is INDV's free cash flow?
Indivior Pharmaceuticals, Inc.'s operating cash flow is $-27.0M, with capital expenditures of $66.0M. FCF margin is -7.5%.
How does INDV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 16.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.71 (avg: 2).